Plato Investment Management Ltd Buys 319 Shares of Boston Scientific Co. (NYSE:BSX)

Plato Investment Management Ltd boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,070 shares of the medical equipment provider’s stock after buying an additional 319 shares during the quarter. Plato Investment Management Ltd’s holdings in Boston Scientific were worth $1,710,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in BSX. SBI Securities Co. Ltd. bought a new position in Boston Scientific during the fourth quarter worth about $214,000. Jones Financial Companies Lllp boosted its position in Boston Scientific by 66.1% during the fourth quarter. Jones Financial Companies Lllp now owns 15,376 shares of the medical equipment provider’s stock worth $1,373,000 after purchasing an additional 6,118 shares during the period. SRS Capital Advisors Inc. boosted its position in Boston Scientific by 168.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,801 shares of the medical equipment provider’s stock worth $161,000 after purchasing an additional 1,130 shares during the period. Smartleaf Asset Management LLC boosted its position in Boston Scientific by 24.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 18,733 shares of the medical equipment provider’s stock worth $1,680,000 after purchasing an additional 3,710 shares during the period. Finally, BlueStem Wealth Partners LLC bought a new position in Boston Scientific during the fourth quarter worth about $1,487,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, CFO Daniel J. Brennan sold 15,087 shares of Boston Scientific stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares in the company, valued at $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 137,322 shares of company stock worth $14,321,068 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on BSX. Truist Financial raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Wells Fargo & Company raised their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Friday. TD Cowen raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Finally, Piper Sandler raised their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $108.91.

Boston Scientific Stock Up 1.0 %

Shares of Boston Scientific stock opened at $104.82 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17. The stock has a market capitalization of $154.69 billion, a price-to-earnings ratio of 83.86, a P/E/G ratio of 2.79 and a beta of 0.80. The company’s 50 day moving average price is $99.57 and its 200-day moving average price is $90.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.